References
- Chen W, Zheng R, Zhang S, et al. The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 2013;32:106–12
- WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701–12
- Neubauer H, Clare SE, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008;10:R85
- Stanczyk FZ. EDITORIAL. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause 2011;18:833–4
- Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;3:230–9
- Neubauer H, Chen R, Schneck H. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Invest 2011;6:185–92
- Ruan X, Schneck H, Schultz S, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol 2012;28:863–6
- Ruan X, Neubauer H, Seeger H, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric 2012;15:467–72
- Neubauer H, Ruan X, Seeger H, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause 2013;20:504–10
- Price T. EDITORIAL. Progesterone receptor membrane component 1: is the metabolism integral to its function and what other steroids are involved. Menopause 2013;20:486–7
- Neubauer H, Ruan X, Seeger H, et al. Possible role of PGRMC1 in breast cancer development. Climacteric 2013;16:1–5
- Zhou J, Yu Q, Chen R, et al. Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. Maturitas 2013;76:129–33
- Chen WY, Manson JE, Hankinson SE, et al. Nurses Health Study. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027–32
- Liu S, Ruan X, Schultz S, et al. Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens. Eur J Contracept Reprod Health 2015;20:29–35
- WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. JAMA 2011;305:1305–14
- Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 2015;22:R1–31